Rituximab-Pvvr (Ruxience)
CD20-directed Cytolytic Antibody class · 0 generic manufacturers · 0 ANDAs filed at FDA.
$42.1M in CY2024 Part D spend5K claims · 2K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Rituximab-Pvvr used for?
Rituximab-Pvvr is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Rituximab-Pvvr?
No. Rituximab-Pvvr is brand-only with no generic equivalents currently in market.
How much does my plan pay for Rituximab-Pvvr?
NADAC pricing data not currently available for this drug.
Is Rituximab-Pvvr on the FDA shortage list?
No. Rituximab-Pvvr is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.